Disruption of nicotine conditioning by dopamine D3 receptor ligands

被引:0
|
作者
B Le Foll
J-C Schwartz
P Sokoloff
机构
[1] Unité de Neurobiologie et Pharmacologie Moléculaire (INSERM U 573),
[2] Centre Paul Broca,undefined
[3] Laboratoire de Physiologie,undefined
[4] Université René Descartes,undefined
来源
Molecular Psychiatry | 2003年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Tobacco smoking is the first cause of preventable death in modern countries. Nicotine replacement therapy or sustained release bupropion helps smoking cessation, but relapse rates are still very high. Nicotine, like other drugs of abuse, activates the dopamine mesolimbic system, which originates in the ventral tegmental area and projects notably to the nucleus accumbens. Situations or environmental stimuli previously associated with cigarette smoking, for example, smell of cigarette smoke, can elicit craving in abstinent smokers and promote relapse. Reducing the effects of nicotine-associated cues might therefore have potential therapeutic utility for smoking cessation. Such an approach has been validated for cocaine in animals, by using the dopamine D3 receptor-selective partial agonist BP 897, which inhibits cocaine cue-induced drug-seeking behavior. Here we show that rats repeatedly injected with nicotine in a particular environment develop nicotine-conditioned locomotor responses, accompanied by an increase in D3 receptor expression in the nucleus accumbens. This conditioned behavior was inhibited by BP 897 or a selective D3 receptor antagonist, suggesting that antagonizing dopamine selectively at the D3 receptor disrupts nicotine-conditioned effects and might represent a novel therapeutic approach for smoking cessation.
引用
收藏
页码:225 / 230
页数:5
相关论文
共 50 条
  • [1] Disruption of nicotine conditioning by dopamine D3 receptor ligands
    Le Foll, B
    Schwartz, JC
    Sokoloff, P
    [J]. MOLECULAR PSYCHIATRY, 2003, 8 (02) : 225 - 230
  • [2] Role of the D3 dopamine receptor in nicotine sensitization
    Smith, Laura N.
    Bachus, Susan E.
    McDonald, Craig G.
    Smith, Robert F.
    [J]. BEHAVIOURAL BRAIN RESEARCH, 2015, 289 : 92 - 104
  • [3] Dopamine D3 receptor ligands with antagonist properties
    Hackling, AE
    Stark, H
    [J]. CHEMBIOCHEM, 2002, 3 (10) : 946 - 961
  • [4] Substituted phenoxyalkylpiperazines as dopamine D3 receptor ligands
    Laszlovszky, I
    Acs, T
    Kiss, B
    Domány, G
    [J]. PHARMAZIE, 2001, 56 (04): : 287 - 289
  • [5] Improving selectivity of dopamine D3 receptor ligands
    Capet, Marc
    Calmels, Thierry
    Levoin, Nicolas
    Danvy, Denis
    Berrebi-Bertrand, Isabelle
    Stark, Holger
    Schwartz, Jean-Charles
    Lecomte, Jeanne-Marie
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2016, 26 (03) : 885 - 888
  • [6] SH3 ligands in the dopamine D3 receptor
    Oldenhof, J
    Ray, A
    Vickery, R
    Van Tol, HHM
    [J]. CELLULAR SIGNALLING, 2001, 13 (06) : 411 - 416
  • [7] Dopamine D3 receptor ligands for the treatment of tobacco dependence
    Le Foll, Bernard
    Goldberg, Steven R.
    Sokoloff, Pierre
    [J]. EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2007, 16 (01) : 45 - 57
  • [8] IODINATED TETRALINS AS D3 DOPAMINE-RECEPTOR LIGANDS
    CHUMPRADIT, S
    KUNG, MP
    MU, M
    VESSOTSKIE, J
    KUNG, HF
    [J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 1994, 208 : 176 - MEDI
  • [9] From virtual to real screening for D3 dopamine receptor ligands
    Byvatov, E
    Sasse, BC
    Stark, H
    Schneider, G
    [J]. CHEMBIOCHEM, 2005, 6 (06) : 997 - 999
  • [10] SYNTHESIS AND RADIOIODINATION OF SELECTIVE LIGANDS FOR THE DOPAMINE D3 RECEPTOR SUBTYPE
    Hocke, C.
    Lober, S.
    Hubner, H.
    Gmeiner, P.
    Kuwert, T.
    Prante, O.
    [J]. JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, 2005, 48 : S93 - S93